SLC2A1 and prostate cancer: Reinicke et al. observed that the expression patterns of GLUT1 and GLUT5 differ in prostate cancer; specifically, GLUT1 expression is reduced in cancer tissues, whereas GLUT5 expression persists in high-grade prostatic intraepithelial neoplasia, implying its potential involvement in early carcinogenic events 144.